Details of the Drug

General Information of Drug (ID: DM5JJ83)

Drug Name

Varespladib

Synonyms

Varespladib; 172732-68-2; LY315920; Varespladib (LY315920); LY-315920; S-5920; VAREPLADIB; 2Q3P98DATH; ({3-[amino(oxo)acetyl]-1-benzyl-2-ethyl-1H-indol-4-yl}oxy)acetic acid; 2-(1-benzyl-2-ethyl-3-oxamoylindol-4-yl)oxyacetic acid; CHEMBL148674; S 5920; 2-((3-(2-amino-2-oxoacetyl)-1-benzyl-2-ethyl-1H-indol-4-yl)oxy)acetic acid; 2-[[3-(2-Amino-2-oxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid; 2-(3-(2-amino-2-oxoacetyl)-1-benzyl-2-ethyl-1H-indol-4-yloxy)acetic acid; SMR004701444; Varespladib [INN]; Varespladib [USAN]; Varespladib [USAN:INN]; UNII-2Q3P98DATH; varespladibum; ((3-(AMINO(OXO)ACETYL)-1-BENZYL-2-ETHYL-1H-INDOL-4-YL)OXY)ACETIC ACID; VRD; VARESPLADIB [MI]; Varespladib (USAN/INN); SCHEMBL26726; VARESPLADIB [WHO-DD]; MLS006010414; MLS006010980; varespladib methyl (A-002); varespladib sodium (A-001); LY 315920 (Varespladib); GTPL9657; DTXSID50169378; EX-A153; CHEBI:189668; BCPP000175; HMS3654E04; HMS3744O03; AMY19698; BCP01854; BDBM50055366; MFCD00944812; s1110; ((3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)acetate; AKOS015842901; compound 6m [PMID: 8978844]; BCP9000883; CCG-268404; DB11909; EX-8676; SB16690; NCGC00346491-01; NCGC00346491-02; NCGC00346491-08; NCGC00346491-12; AC-32931; AS-16956; HY-13402; A-001; FT-0659937; SW219559-1; A25228; D08107; EN300-144829; J-010846; Q7915613; BRD-K09711437-001-01-9; Z1721255146; (3-Aminooxalyl-1-benzyl-2-ethyl-1H-indol-4-yloxy)-acetic acid; 2-[2-ethyl-3-oxamoyl-1-(phenylmethyl)indol-4-yl]oxyethanoic acid; ((3-(Aminooxoacetyl)-1-benzyl-2-ethyl-1H-indol-4-yl)oxy)acetic acid; (3-Aminooxalyl-1-benzyl-2-ethyl-2,3-dihydro-1H-indol-4-yloxy)-acetic acid; 2-{[1-benzyl-3-(carbamoylcarbonyl)-2-ethyl-1H-indol-4-yl]oxy}acetic acid; ACETIC ACID, ((3-(AMINOOXOACETYL)-2-ETHYL-1-(PHENYLMETHYL)-1H-INDOL-4-YL)OXY)-; Acetic acid, ((3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)-,; LY 315920; Varespladib; 2-[[3-(2-Amino-2-oxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic aci

Indication

Disease Entry	ICD 11	Status	REF
Snakebite	N.A.	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C21H20N2O5
Canonical SMILES: CCC1=C(C2=C(N1CC3=CC=CC=C3)C=CC=C2OCC(=O)O)C(=O)C(=O)N
InChI: InChI=1S/C21H20N2O5/c1-2-14-19(20(26)21(22)27)18-15(9-6-10-16(18)28-12-17(24)25)23(14)11-13-7-4-3-5-8-13/h3-10H,2,11-12H2,1H3,(H2,22,27)(H,24,25)
InChIKey: BHLXTPHDSZUFHR-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 155815
TTD ID: D74PRE

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phospholipase A2 (PLA2G1B)	TT9V5JH	PA21B_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Snakebite

ICD Disease Classification

N.A.

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Phospholipase A2 (PLA2G1B)	DTT	PLA2G1B	2.65E-01	-0.08	-0.21

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05717062) Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous Varespladib Followed by Oral Varespladib in Addition to Standard of Care in Subjects Bitten by Venomous Snakes. U.S.National Institutes of Health.
2	Varespladib in the Treatment of Snakebite Envenoming: Development History and Preclinical Evidence Supporting Advancement to Clinical Trials in Patients Bitten by Venomous Snakes. Toxins (Basel). 2022 Nov 11;14(11):783.